WVE-007 (INHBE siRNA)
Obesity / Metabolic Disease
Phase 1Active - INLIGHT trial; Positive interim data reported
Key Facts
Indication
Obesity / Metabolic Disease
Phase
Phase 1
Status
Active - INLIGHT trial; Positive interim data reported
Company
About WaVe Life Sciences
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Its core strategy is built on the PRISM® platform, a toolkit for designing and developing stereopure oligonucleotides, including RNA editing and silencing therapies. The company is rapidly advancing a diversified pipeline, with key programs like WVE-006 for Alpha-1 antitrypsin deficiency and WVE-007 (INHBE siRNA) for obesity generating significant clinical interest. Wave is strategically positioning itself at the forefront of next-generation genetic medicines.
View full company profile